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OBJECTIVE: EQ-5D has become a standardised instrument for
measuring quality of life (QoL). Actually there is no data avail-
able for Austrian diabetic patients. We surveyed QoL of diabetic
patients in an outpatient clinic in Styria and applied EQ-5D the
ﬁrst time in such a setting. Aim of the survey was to gain insights
the overall QoL in this patient group and testing the practical-
ity and understandability of EQ-5D in an Austrian outpatient
clinic setting. METHODS: EQ-5D and EQ-VAS were used to
measure QoL at a random sample visiting the outpatient clinic
within the 12 weeks of survey. The form was handed out in hard-
copy to n = 103 patients (7% in-patient, 93% out-patient) during
the waiting time for consultation. All 103 patients responded 
to the form. RESULTS: Rate of completed questions was high,
94% responded to mobility, 95% to personal care, 93% to usual
activities, 92% to anxiety/depression and 86% to VAS-Score. 
It turned out that VAS was the most difﬁcult question for the
patients to assign. 24% of patients had Diabetes mellitus (DM)
1 (39% women) with a mean age of 43 (SD ± 13) years, 75%
of patients with DM2 (53% women) were mean 65 (SD ± 12)
years old, in 1% of patients DM type was missing. Mean QoL
measured with VAS-Score was in patients with DM1 82 (±15),
Median 83 (80–90) and mean QoL 62 (±21), Median 63 (50–80)
for patients with DM2. Patients with DM1 had a signiﬁcantly
higher QoL (p < 0.001, Wilcoxon test) than patients with DM2.
CONCLUSION: The survey showed that EQ-5D can be easily
integrated in the operating processes of an outpatient clinic and
all patients were willing to ﬁll out the EQ-5D. In a next step EQ-
5D will be linked to medical data to gain more information
about EQ-5D and medical situation.
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VERSUS METFORMIN+GLIMEPIRIDE IN TYPE-2 PATIENTS
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OBJECTIVES: Poor glycemic control is associated with
increased risk of complications in Type-2 diabetes. A recent clin-
ical trial demonstrated that Liraglu-tide+Metformin (Lira/Met)
versus Metformin (Met) signiﬁcantly improved HbA1c (0.82%-
points lower after 5 weeks). In the same study Lira/Met versus
Met-formin+Glimipiride (Met/SU) signiﬁcantly improved weight
by approximately 3%-points. The objective is to link these short-
term outcomes to long-term complication rates. METHODS:
A validated model which project long-term complications,
improvements in Life-Years Gained (LYG) and Quality-Adjusted
Life Years (QALY). Standard Markov modeling was used to
describe incidence and progression of com-placations (cardio-
vascular disease, neuropathy, renal and eye disease). Probabili-
ties of complications and HbA1c-dependent adjustments were
derived from the DCCT, UKPDS, and WESDR studies. Clinical
input was taken from a 5 week double-blind, double-dummy,
randomized, parallel-group, dose titration study with an open la-
belled OHA arm phase II trial in Type-2 patients. Outcomes were
estimated at 3% per annum and beneﬁts were projected over
patients’ lifetime. RESULTS: Improved glycemic control and
weight proﬁle with Lira/Met versus Met and versus Met/SU, re-
specify, led to decreased diabetes-related complications, with a
subsequent in-crease in LYG of 0.33 and 0.29 QALYs compared
to Met and 0.18 LYG and 0.14 QALY compared to Met/SU.
CONCLUSION: Improvements in glycemic control and weight
led to long-term improvement of both LYG and QALY when
comparing Lira/Met treat-mint to Met and Met/SU treatment.
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OBJECTIVES: The objective of this study was to assess the
impact of early basal insulinisation with Lantus in people with
type-2 diabetes failing to reach optimal glucose control with oral
therapy. METHODS: The Canadian INSIGHT study was a 24-
week trial of patients with Type-2 diabetes randomized to receive
insulin glargine added to current therapy, or adjusted oral
therapy. Nineteen endocrinologists or experts selected 34 family
physicians for a mentor/preceptor relationship, facilitating
insulin initiation. Treatment satisfaction (TS) and quality of life
(QoL) were also assessed for all 405 patients randomized to
either the glargine (206) or the adjusted oral therapy arm (199).
TS and QoL were assessed using the Diabetes Treatment Satis-
faction Questionnaire (DTSQ) and the Audit of Diabetes Depen-
dant QoL (ADDQoL) questionnaire. Both self-administered
questionnaires were administered at baseline, week 12 and 24.
A total of 376 and 364 patients completed the DTSQ and the
ADDQoL questionnaires, respectively. RESULTS: At baseline,
TS and QoL were similar in both treatment arms. A1c reduction
was greater with glargine (p < 0.001). The total DTSQ score and
the TS items (items 1, 4, to 8) improved from baseline in both
treatment arms (p < 0.001); however, there was signiﬁcantly
more satisfaction with treatment with insulin glargine for the
DTSQ total score (p = 0.024) and the TS items (p = 0.011). Per-
ceived frequency of hyperglycaemia and hypoglycaemia (DTSQ
items 2 and 3) were signiﬁcantly (P < 0.05) lower at week 12
and 24 for all subjects with no distinguishable differences for the
two treatment arms at week 24. Only perceived hyperglycemia
was signiﬁcantly (P < 0.01) lower for glargine at week 12. Finally,
overall QoL improved in both groups (p < 0.001); however,
glargine had a greater impact at week 12 (p = 0.025) and end-
point (p = 0.024). CONCLUSIONS: Improving glucose control
with glargine had a positive impact on TS and general QoL
without complaints related to hypoglycemia.
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